Intended for healthcare professionals

  1. Research
  2. Risk of fatal coronary...
  3. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.
Research Article

Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.

British Medical Journal 1991; 303 doi: https://doi.org/10.1136/bmj.303.6807.893 (Published 12 October 1991) Cite this as: British Medical Journal 1991;303:893

Related articles

See more

Cited by...

  • Efficacy, Safety and Cost-effectiveness of Atorvastatin 40mg versus 80 mg in South Asian Patients with acute coronary syndrome: A protocol for randomised clinical trial
  • Impact of changes in Achilles tendon thickening on cardiovascular events in patients with familial hypercholesterolemia
  • Familial hypercholesterolaemia
  • Genetic testing for familial hypercholesterolemia in Quebec, Canada: a single-centre retrospective cohort study
  • A comparison of the Netherlands, Norway and UK Familial Hypercholesterolemia screening programmes with implications for target setting and the UKs NHS Long Term Plan
  • Analysis of a paediatric cohort of dyslipidaemic patients using unsupervised learning methods provides insights into the biochemical phenotypes of familial hypercholesterolemia
  • Familial hypercholesterolaemia: a study protocol for identification and investigation of potential causes and markers of subclinical coronary artery disease in the Faroe Islands
  • Innovative, centralised, multidisciplinary medicines optimisation clinic for PCSK9 inhibitors
  • An LDLR missense variant poses high risk of familial hypercholesterolemia in 30% of Greenlanders and offers potential for early cardiovascular disease intervention
  • Comparing the performance of the novel FAMCAT algorithms and established case-finding criteria for familial hypercholesterolaemia in primary care
  • Application of a risk stratification tool for familial hypercholesterolaemia in primary care: an observational cross-sectional study in an unselected urban population
  • The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification
  • Familial hypercholesterolaemia: history, diagnosis, screening, management and challenges
  • Children with familial hypercholesterolemia display changes in LDL and HDL function: a cross-sectional study
  • Decision to reject screening for familial hypercholesterolaemia is flawed
  • Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study
  • Familial hypercholesterolemia: Detect, treat, and ask about family
  • Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia
  • Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction
  • Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia
  • Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel
  • Genetically Confirmed Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome
  • Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study
  • Putting Into Perspective the Hazards of Untreated Familial Hypercholesterolemia
  • Long-Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening
  • Genetic identification of familial hypercholesterolemia within a single U.S. health care system
  • Statins in Familial Hypercholesterolemia: Translating Evidence to Action
  • Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia Phenotype
  • Feasibility of improving identification of familial hypercholesterolaemia in general practice: intervention development study
  • Improving the Monitoring and Care of Patients With Familial Hypercholesterolemia
  • Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES)
  • Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France
  • Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use?
  • The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association
  • Universal Screening for Familial Hypercholesterolemia in Children
  • Refinement of Variant Selection for the LDL Cholesterol Genetic Risk Score in the Diagnosis of the Polygenic Form of Clinical Familial Hypercholesterolemia and Replication in Samples from 6 Countries
  • The Severe Hypercholesterolemia Phenotype: Clinical Diagnosis, Management, and Emerging Therapies
  • Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis
  • Familial hypercholesterolaemia presenting with coronary artery disease in a young patient
  • Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia
  • Low Prevalence of Mutations in Known Loci for Autosomal Dominant Hypercholesterolemia in a Multiethnic Patient Cohort
  • Low-Density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial
  • Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia: Results of a Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety as Add-On Therapy in Patients With Coronary Artery Disease
  • Familial hypercholesterolaemia
  • Paediatric screening for hypercholesterolaemia in Europe
  • Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies
  • CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia
  • Identifying patients with familial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre
  • The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men
  • Candidate Gene Genotypes, Along with Conventional Risk Factor Assessment, Improve Estimation of Coronary Heart Disease Risk in Healthy UK Men
  • Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk
  • Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease.
  • Tendon Xanthomas in Familial Hypercholesterolemia Are Associated With Cardiovascular Risk Independently of the Low-Density Lipoprotein Receptor Gene Mutation
  • Risk of Fatal Stroke in Patients With Treated Familial Hypercholesterolemia: A Prospective Registry Study * Editorial Comment
Back to top